Association Between Phenotypic Age and the Risk of Mortality in Patients With Heart Failure: A Retrospective Cohort Study

Xu, Xuhong; Xu, Zhiqi

doi:10.1002/clc.24321

Cited by 3 publications

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study

Tong,

Xue,

Wang

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

Background The process of biological aging in patients diagnosed with chronic liver disease remains unclear. Aim The current study aims to investigate if there is an accelerated biological aging process in participants with advanced fibrosis (AF) and metabolic dysfunction-associated steatotic liver disease (MASLD). Methods Data from the 2017–2018 NHANES cycle were analyzed. AF was determined based on the values of liver stiffness measurement (LSM) and MASLD was defined according to new consensus nomenclature. Klemera-Doubal method biological age (KDM bioage) and Phenotypic age (Phenoage) were adopted to quantify biological age. Phenoage advancement (Phenoage_advance) and KDM advancement (KDM_advance) were generated as the difference between the calculated biological age and chronological age, and a positive residual was regarded as an indicator of accelerated biological aging. Results A total of 3974 participants was enrolled. The weight mean KDM_advance and phenoage_advance in AF group was 4.22 years (95%CI: 2.96–5.49 years) and 2.61 years (95%CI: 1.80–3.41 years), while in MASLD group was 0.37 years (95%CI: -0.28–1.03 years) and 0.04 years (95%CI: -0.64–0.72 years), respectively. Multivariate linear regression analysis showed that participants with AF had older KDM_advance and phenoage_advance compared with those without AF (1.50 years (95%CI: 0.23–2.77 years), P = 0.02; 1.00 years (95%CI: 0.18–1.82 years), P = 0.02; respectively), in models adjusting demographic characteristics, socioeconomic status, lifestyle factors, and comorbidities. No significant association was found between MASLD and KDM_advance and phenoage_advance. Conclusions AF, not MASLD, was independently associated with accelerated biological aging in adults from a US representative sample. Supplementary Information The online version contains supplementary material available at 10.1186/s12889-024-20808-y.

show abstract

Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study

Tong,

Xue,

Wang

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

show abstract

Nonlinear relationship between phenotypic age acceleration and testosterone deficiency in the US population: A cross-sectional NHANES study

Zhou,

Cai,

Zheng

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective This study aims to assess the relationship between Phenotypic age acceleration (PhenoAgeAccel) and testosterone deficiency (TD) in US male, using National Health and Nutrition Examination Survey (NHANES) data from 2015 to 2016. Methods This study explored the relationship between PhenoAgeAccel and TD by analyzing a sample reflecting the male population of the United States (n = 1,402; NHANES 2015–2016). Phenotypic age (PA) is calculated using nine blood-based biomarkers. PhenoAgeAccel was calculated by extracting the residuals and regressing the phenotypic age on the chronological age (CA). TD was defined as serum testosterone levels below 300 ng/dL, in accordance with the criteria set forth by the AUA. This research used multivariable logistic models to examine the connection between PhenoAgeAccel and TD. Additionally, it included subgroup and interaction analyses to assess variations among different groups. Smoothed curve fitting and generalized additive modelling (GAM) were also employed to analyze the data further. Results The study included 1,402 subjects, with 293 diagnosed with TD and 1,109 without. The weighted multivariate logistic regression model indicated an 8% higher probability of TD for each unit increase in PhenoAgeAccel (OR: 1.08, 95% CI: 1.05–1.11) after accounting for all covariates. Subgroup analysis outcomes were uniform across various categories, demonstrating a significant positive relationship between PhenoAgeAccel and TD. Interaction tests showed that the positive link between PhenoAgeAccel and TD remained consistent with all interaction P-values exceeding 0.05. Also, a non-linear relationship between PhenoAgeAccel and TD was discovered, with a progressive increase in the risk of TD with elevated PhenoAgeAccel, exhibiting a J-shaped curve (inflection point: -9.26, p < 0.05). Conclusions Our study suggests that an increase in PhenoAgeAccel may be correlated with a heightened likelihood of developing TD. Consequently, PhenoAgeAccel could potentially serve as a valuable biomarker for the early identification of individuals at risk of TD, with implications for clinical management and public health nutrition strategies.

show abstract

Association between phenotypic age and mortality risk in individuals with obesity: a retrospective cohort study

Huang,

Zhou,

Huang

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

ObjectiveThis study investigates the association between phenotypic age acceleration (PAA) and all-cause and cause-specific mortality in obese individuals.MethodsData were drawn from the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2018, including 9,925 obese adults (BMI ≥ 30 kg/m2). PAA, defined as phenotypic age exceeding chronological age, was assessed using clinical biomarkers. Kaplan-Meier survival analysis and Cox proportional hazards models were used to assess the relationship between PAA and all-cause, cardiovascular, and cancer mortality, adjusting for covariates such as age, gender, race, lifestyle, and health status. Subgroup and sensitivity analyses were performed to ensure the robustness of the findings.ResultsDuring a median follow-up of 10.6 years, 1,537 deaths were recorded, including 419 from cardiovascular disease and 357 from cancer. PAA was significantly associated with all-cause mortality (HR = 1.84, 95% CI: 1.64–2.06), cardiovascular mortality (HR = 1.86, 95% CI: 1.50–2.31), and cancer mortality (HR = 1.47, 95% CI: 1.17–1.85). These associations remained significant after adjusting for multiple variables, and sensitivity analyses confirmed the robustness of the results.ConclusionPAA is an independent predictor of all-cause, cardiovascular, and cancer mortality in obese individuals. This study highlights the importance of PAA in mortality risk assessment and health management in the obese population.

show abstract

Association Between Phenotypic Age and the Risk of Mortality in Patients With Heart Failure: A Retrospective Cohort Study

Cited by 3 publications

References 48 publications

Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study

Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study

Nonlinear relationship between phenotypic age acceleration and testosterone deficiency in the US population: A cross-sectional NHANES study

Association between phenotypic age and mortality risk in individuals with obesity: a retrospective cohort study

Contact Info

Product

Resources

About